INTERMITTENT INTERFERON-αα USE IN RENAL METASTASES
https://doi.org/10.17650/1726-9776-2009-5-2-31-35
Abstract
The immediate and late results of treating patients with renal metastases with a new intermittent interferon-α (IFN-α) use regimen are presented.
Subjects and methods. The study included 131 patients receiving IFN-α as 3106 IU subcutaneously, days 1—10 at a further 2-week inter- val.
Results. Complete and partial effects were achieved in 11 (8.4%) and 18 (13.7%) patients, respectively; stable disease (≥6 months) was observed in 35 (26.7%). The median time to progression was 23.3 months. The sizes and number of lung metastases were found to have a great impact on survival: with metastases sizing ≤2 cm and their number of ≤10, the median overall survival was 29.9 months. These patients are the most promising candidates for the effective first-line IFN-α therapy.
About the Authors
S. L. Gutorov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Department of Chemotherapy and Combined Treatments for Malignancies
Russian Federation
Department of Chemotherapy and Combined Treatments for Malignancies
Ye. V. Chernoglazova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Department of Chemotherapy and Combined Treatments for Malignancies
Russian Federation
Department of Chemotherapy and Combined Treatments for Malignancies
N. A. Vetrova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Department of Chemotherapy and Combined Treatments for Malignancies
Russian Federation
Department of Chemotherapy and Combined Treatments for Malignancies
References
1. Parkin D.M., Bray F., Ferlay J. et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74—108.
2. Parton M., Gore M., Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 2006;24:5584—92.
3. Cohen H.T., McGovern F.J. Renal-cell carcinoma. N Engl J Med 2005;353: 2477—90.
4. Glaspy J.A. Therapeutic options in the management of renal cell carcinoma. Semin Oncol 2002;29:41—6.
5. Small E.J., Motzer R.J. Interferon for renal cell carcinoma. In: Belldegrun A., Ritchie A.W.S., Figlin R.A. et al. (eds). Renal and adrenal tumors. New York: Oxford University Press, 2003. p. 381—7.
6. Saitoh H., Hida M., Nakamura K. et al. Metastatic processes and a potential indi- cation of treatment for metastatic lesions of renal adenocarcinoma. J Urol 1982;128(5):916—8.
Review
For citations:
Gutorov S.L., Chernoglazova Ye.V., Vetrova N.A. INTERMITTENT INTERFERON-αα USE IN RENAL METASTASES. Cancer Urology. 2009;5(2):31-35. (In Russ.) https://doi.org/10.17650/1726-9776-2009-5-2-31-35
Views:
1313
Email this article 